CA2074188A1 - Vector with multiple tat activation response elements affecting gene expression - Google Patents

Vector with multiple tat activation response elements affecting gene expression

Info

Publication number
CA2074188A1
CA2074188A1 CA002074188A CA2074188A CA2074188A1 CA 2074188 A1 CA2074188 A1 CA 2074188A1 CA 002074188 A CA002074188 A CA 002074188A CA 2074188 A CA2074188 A CA 2074188A CA 2074188 A1 CA2074188 A1 CA 2074188A1
Authority
CA
Canada
Prior art keywords
response elements
vector
construct
activation response
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002074188A
Other languages
French (fr)
Other versions
CA2074188C (en
Inventor
Julianna Lisziewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Commerce
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2074188A1 publication Critical patent/CA2074188A1/en
Application granted granted Critical
Publication of CA2074188C publication Critical patent/CA2074188C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to viral inhibition, particularly HIV inhibition, by DNA sequences including multiple target response elements. This is the first time that a construct, proposed for gene therapy use, is under the control of a biological regulation. The protective gene product will only be expressed, if the cell becomes infected and a viral protein is made. The DNA construct of the present invention comprises a vector and a promoter operably linked to multiple tat activation response elements so that the elements are transcribed in tandem.
The DNA construct can be used in the treatment of viral infections, in particular HIV associated diseases, by obtaining cells from an HIV-infected patient, transforming the cells with the construct and administering the transformed cell to the patient.
CA002074188A 1990-01-18 1991-01-16 Vector with multiple tat activation response elements affecting gene expression Expired - Fee Related CA2074188C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46740790A 1990-01-18 1990-01-18
US467,407 1990-01-18
US59629990A 1990-10-15 1990-10-15
US596,299 1990-10-15
PCT/US1991/000175 WO1991010453A1 (en) 1990-01-18 1991-01-16 Vector with multiple target response elements affecting gene expression

Publications (2)

Publication Number Publication Date
CA2074188A1 true CA2074188A1 (en) 1991-07-19
CA2074188C CA2074188C (en) 2004-05-11

Family

ID=27042041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002074188A Expired - Fee Related CA2074188C (en) 1990-01-18 1991-01-16 Vector with multiple tat activation response elements affecting gene expression

Country Status (6)

Country Link
EP (1) EP0511285A4 (en)
JP (1) JP2746480B2 (en)
KR (1) KR0148782B1 (en)
AU (1) AU642959B2 (en)
CA (1) CA2074188C (en)
WO (1) WO1991010453A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070533A1 (en) 2009-12-10 2011-06-16 International Centre For Genetic Engineering And Biotechnology (Icgeb) Peptides and their derivatives inhibiting extracellular release of hiv-1 tat protein and hiv-1 replication

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454781B1 (en) * 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
US6251675B1 (en) 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US6245560B1 (en) * 1990-01-18 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Vector with multiple target response elements affecting gene expression
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
GB9319772D0 (en) * 1993-09-24 1993-11-10 Therexsys Ltd Therapeutic agent
US5877018A (en) * 1994-10-20 1999-03-02 Connaught Laboratories Limited Synthetic eukaryotic promoters containing two inducible elements
NZ315890A (en) * 1995-08-25 1998-10-28 Univ California Chimeric antiviral agents which incorporate rev binding nucleic acids
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
EP1857549B1 (en) * 1998-03-20 2018-10-17 Commonwealth Scientific and Industrial Research Organisation Control of gene expression
AU9196798A (en) * 1998-05-04 1999-11-23 Julianna Lisziewicz Chimeric decoy rnas having synergistic anti-hiv activity
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
CN101213212A (en) 2005-02-15 2008-07-02 西蒙有限公司 Methods and compositions for impairing multiplication of HIV-1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070533A1 (en) 2009-12-10 2011-06-16 International Centre For Genetic Engineering And Biotechnology (Icgeb) Peptides and their derivatives inhibiting extracellular release of hiv-1 tat protein and hiv-1 replication

Also Published As

Publication number Publication date
EP0511285A4 (en) 1993-05-26
KR920703118A (en) 1992-12-17
KR0148782B1 (en) 1998-08-17
JP2746480B2 (en) 1998-05-06
JPH05504255A (en) 1993-07-08
AU642959B2 (en) 1993-11-04
AU7074091A (en) 1991-08-05
CA2074188C (en) 2004-05-11
WO1991010453A1 (en) 1991-07-25
EP0511285A1 (en) 1992-11-04

Similar Documents

Publication Publication Date Title
CA2074188A1 (en) Vector with multiple tat activation response elements affecting gene expression
Okamoto et al. Regulation of NF-κB and disease control: identification of a novel serine kinase and thioredoxin as effectors for signal transduction pathway for NF-κB activation
EP0400958A3 (en) Live vaccines
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
CA2087272A1 (en) Cd53 cell surface antigen and use thereof
WO1995000638A3 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
IE842193L (en) Plasmid with tandem promoter system
BG44877A3 (en) METHOD FOR EXPRESSING A GENE ENCODING HUMAN IMMUNE INTERFERON
HUP9902310A2 (en) Complementary adenoviral vector systems and cell lines
NO954217L (en) Guanosine-rich antivirus oligonucleotides
CA2130360A1 (en) Sulfonic Acid Derivatives in the Treatment of Viral Diseases
FR2700169B1 (en) New TAT trans-dominant variants of the human immunodeficiency virus.
BR9806866A (en) Expression cassette and its use, expression cassette strain, nucleic acid vector, viral strain, pharmaceutical composition, and, processes to study the function of one or more heterologous genes in a eukaryotic cell, to produce an hsv strain, for treating the human or animal body and for performing gene therapy on a human or animal, and, vaccine.
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
CA2045323A1 (en) Non-a, non-b hepatitis virus genomic cdna and antigen polypeptide
CA2215328A1 (en) Novel human cytomegalovirus dna sequences
EP0804613A4 (en) Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
JPS5519239A (en) Interferon-producing attractant
Guy et al. DNA Binding Factors That Bind to the Negative Regulatory Element of the Human Immunodeficiency Virus-1: Regulation by: nef
CN102821783B (en) Treatment HIV infects and the related indication fusion of AIDS and method
KR950701345A (en) Novel peptide having elastase inhibitory activity and method for producing the same
Weil et al. Interferon induction of (2′–5′) oligoisoadenylate synthetase in diploid and trisomy 21 human fibroblasts: Relation to dosage of the interferon receptor gene (IRFC)
Stevens Transcripts associated with herpes simplex virus latency
EP0372904A3 (en) Protease, reverse transcriptase, and endonuclease of retroviruses and method for producing these enzymes
EP0404119A3 (en) Plasma-type glutathione peroxidase gene and application of the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed